Rocket Pharmaceuticals (RCKT) Profit After Tax (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Profit After Tax data on file, last reported at -$47.6 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 22.4% year-over-year to -$47.6 million; the trailing twelve-month figure through Mar 2026 stood at -$209.4 million (up 18.85% YoY), and the FY2025 full-year result was -$223.1 million, up 13.77% from the prior year.
• Profit After Tax retreated to -$47.6 million in Q1 2026, from -$42.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$42.5 million in Q4 2025 to a low of -$69.6 million in Q2 2024.
• A 5-year average of -$58.6 million and a median of -$60.3 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 57.57% in 2022 and advanced 29.49% in 2025, its largest moves.
• Tracing RCKT's Profit After Tax over 5 years: stood at -$66.7 million in 2022, then gained by 10.59% to -$59.7 million in 2023, then decreased by 1.12% to -$60.3 million in 2024, then increased by 29.49% to -$42.5 million in 2025, then slipped by 11.89% to -$47.6 million in 2026.
• Business Quant data shows RCKT's Profit After Tax at -$47.6 million in Q1 2026, -$42.5 million in Q4 2025, and -$50.3 million in Q3 2025.